A simulated tobramycin dosing regimen of 3.5 mg/kg/dose every 12 hours optimally achieved the target peak concentration of 8-12 mg/L in 64.2% of infants with congenital heart disease, though dose adjustments are required for eGFR <90 mL/min/1.73 m2.
Observational (n=55)
No
Does a specific intravenous tobramycin dosing regimen achieve optimal pharmacokinetic targets in infants with congenital heart disease in the cardiac intensive care unit?
In infants with congenital heart disease in the CICU, a tobramycin dosing regimen of 3.5 mg/kg/dose every 12 hours optimally achieves therapeutic PK/PD targets, with dose adjustments required for eGFR <90 mL/min/1.73 m2.
Abstract Background Aminoglycoside pharmacokinetic data are limited in infants with congenital heart disease (CHD). This study aimed to characterize tobramycin pharmacokinetics and determine optimal intravenous dosing for infants in the cardiac intensive care unit (CICU). Methods A population pharmacokinetic analysis was performed in infants >1 month to <12 months of age initiated on intravenous conventional dosing tobramycin in the CICU from January 1, 2020, through December 31, 2024. Simulations were performed to determine dosage regimens achieving the desired peak (8–12 mg/L) and trough (<1 mg/L) concentrations. Regimens were also evaluated in achieving secondary targets based on the area under the concentration-time curve (AUC). Results Fifty-five infants, with a median age of 3.5 months and a weight of 5.1 kg, were included. Twenty (36.4%) patients were premature. A two-compartment model best described the pharmacokinetic data, with weight and eGFR identified as significant covariates for clearance. A 3.5 mg/kg/dose every-12-hour regimen optimally obtained target peak and trough concentration, and AUC targets. Infants with eGFRs <90 mL/min/1.73 m 2 required adjustments to meet targets at adequate rates. Conclusion Tobramycin pharmacokinetics in CHD infants were comparable to published data on non-CHD infants. A 3.5 mg/kg/dose every-12-hour regimen was optimal, with dose adjustments needed for eGFR <90 mL/min/1.73 m 2 . Impact Tobramycin pharmacokinetic data are limited in infants with congenital heart disease (CHD). A dosing regimen of 3.5 mg/kg/dose every 12 hours for intravenous tobramycin achieves therapeutic targets in infants aged 1 month to 1 year with CHD in the cardiac intensive care unit (CICU). Infants with estimated glomerular filtration rates <90 mL/min/1.73 m 2 required dose adjustments to meet targets at adequate rates. This study aimed to characterize the pharmacokinetics of tobramycin in infants in the CICU, highlighting weight and renal function as significant covariates for individualized dosing.
Malehorn et al. (Thu,) conducted a observational in Congenital heart disease (n=55). Tobramycin was evaluated on Attainment of target peak (8-12 mg/L) and trough (<1 mg/L) concentrations. A simulated tobramycin dosing regimen of 3.5 mg/kg/dose every 12 hours optimally achieved the target peak concentration of 8-12 mg/L in 64.2% of infants with congenital heart disease, though dose adjustments are required for eGFR <90 mL/min/1.73 m2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: